BioLineRx Ltd. (BLRX)
- Previous Close
3.1000 - Open
3.0106 - Bid --
- Ask --
- Day's Range
3.0106 - 3.1600 - 52 Week Range
2.3000 - 35.6000 - Volume
12,708 - Avg. Volume
31,801 - Market Cap (intraday)
11.971M - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-6.0000 - Earnings Date Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.00
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
www.biolinerx.comRecent News: BLRX
View More
Performance Overview: BLRX
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BLRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BLRX
View MoreValuation Measures
Market Cap
11.93M
Enterprise Value
7.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.21
Price/Book (mrq)
0.85
Enterprise Value/Revenue
0.26
Enterprise Value/EBITDA
1.89
Financial Highlights
Profitability and Income Statement
Profit Margin
-31.86%
Return on Assets (ttm)
-23.28%
Return on Equity (ttm)
-69.11%
Revenue (ttm)
28.94M
Net Income Avi to Common (ttm)
-9.22M
Diluted EPS (ttm)
-6.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
19.56M
Total Debt/Equity (mrq)
111.73%
Levered Free Cash Flow (ttm)
-43.89M